About this condition
Polycystic Kidney Disease — Genetic Testing
Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 individuals — making it the most common life-threatening monogenic kidney disease. PKD1 (chromosome 16p13.3) accounts for ~85% of cases with more severe disease (median ESRD at age 54). PKD2 (chromosome 4q22.1) accounts for ~15% with milder disease (median ESRD at age 74). This 20-year difference in kidney failure timeline makes genotyping critical for prognosis and planning.
Tolvaptan (Jynarque, V2 receptor antagonist) is FDA-approved to slow kidney growth and decline in eGFR in ADPKD. Tolvaptan eligibility requires evidence of rapidly progressive disease — PKD1 genotype with truncating mutations predicts rapid progression and supports tolvaptan initiation. PKD2 patients with slow progression may not benefit from tolvaptan's side effects (massive aquaresis, hepatotoxicity monitoring).
PKD1 sequencing is technically challenging due to six PKD1-like pseudogenes (PKD1P1-P6) sharing >97% homology with PKD1 exons 1-34. Standard NGS panels may mismap reads between PKD1 and pseudogenes. Long-range PCR-based enrichment or whole-genome approaches with sophisticated bioinformatics improve PKD1 variant detection accuracy.
PKD1 truncating mutations = median ESRD at 54. PKD2 = median ESRD at 74. This 20-year difference drives treatment urgency, transplant planning, and tolvaptan eligibility. Genotype predicts your kidney future.
- Gene locus
- PKD1 (16p13.3), PKD2 (4q22.1)
